Claims:

1. A nasal pharmaceutical composition for intranasal administration comprising alcaftadine or a pharmaceutically acceptable salt thereof, a mucoadhesive agent and a preservative,
wherein the mucoadhesive agents is included in the composition in an amount from 0.01% to 10% by weight.

2. The composition of claim 1, wherein the alcaftadine is in free form.

3. The composition of claim 1 or 2, wherein the mucoadhesive agent is selected from hydroxypropylmethyl cellulose, hydroxyethylcellulose, carboxymethylcellulose sodium, povidone, chitosan, guar gum, xanthan gum, and any combination of any of the foregoing.

4. The composition of any one of the preceding claims, wherein the mucoadhesive agent is hydroxypropylmethyl cellulose.

5. The composition of any one of claims 1-3, wherein the mucoadhesive agent is carboxymethylcellulose sodium.

6. The composition of any one of the preceding claims, wherein the mucoadhesive agent has a viscosity of 1 to 20 cPs.

7. The composition of any of the preceding claims, further comprising at least 0.0125% w/w benzalkonium chloride, based upon the total weight of the composition.

8. The composition of any of the preceding claims, further comprising a buffering agent, a tonicity adjustment agent, a chelating agent, or any combination of any of the foregoing.

9. The composition of claim 8, wherein the buffering agent is monobasic sodium phosphate.

10. The composition of claim 8 or 9, wherein the tonicity adjustment agent is sodium chloride.

11. The composition of any one of claims 8-10, wherein the chelating agent is disodium edetate.

12. The composition of any one of the preceding claims, wherein the viscosity of the composition is from about 1.5 to about 4.0 cPs.

13. The composition of any one of the preceding claims, wherein the pH of the composition is from about 6.3 to about 7.3.

14. An aqueous nasal pharmaceutical composition comprising (i) about 0.1 to 1.0% w/w alcaftadine or a pharmaceutically acceptable salt thereof, (ii) about 0.01 to 1.0% w/w hydroxypropyl methyl cellulose, (iii) about 0.068 to about 6.8% w/w of sodium chloride, (iv) about 0.0019 to about 0.19% w/w monobasic sodium phosphate, (v) about 0.005 to about 0.5% w/w disodium edetate, and (vi) about 0.0025 to about 0.25% w/w benzalkonium chloride, wherein the composition has a pH of 6.3 to 7.3.

15. The composition of claim 14, wherein the hydroxypropylmethyl cellulose has a viscosity of 1 to 20 cPs.

16. The composition of claim 14 or 15, wherein the viscosity of the composition is from about 1.5 to about 4.0 cPs.

17. The composition of any of the preceding claims for use in the treatment of allergic rhinitis or one or more symptoms thereof.

18. The composition of any of the preceding claims for use in the treatment of nasal congestion.

19. Use of an effective amount of the nasal pharmaceutical composition of any one of claims 1-16 in the manufacture of a medicament for treating allergic rhinitis or one or more symptoms thereof in a patient in need thereof.

20. Use of an effective amount of the nasal pharmaceutical composition of any one of claims 1-16 in the manufacture of a medicament for treating nasal congestion in a patient in need thereof.